# Persistence of Hepatitis B Antibody Levels & Immune Response to a Hepatitis B Vaccine Challenge

> **NCT00411697** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 301 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** Engerix™-B Kinder

## Key facts

- **NCT ID:** NCT00411697
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2007-05
- **Final completion:** 2007-05
- **Target enrollment:** 301 (ACTUAL)
- **Last updated:** 2016-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00411697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00411697, "Persistence of Hepatitis B Antibody Levels & Immune Response to a Hepatitis B Vaccine Challenge". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00411697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*